Cocrystal Pharma, INC. (COCP) — 10-K Filings

All 10-K filings from Cocrystal Pharma, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.

10-K Filings (3)

Cocrystal Pharma Faces CRO Dispute Amidst Mixed Clinical Trial Results — Mar 31, 2026 Risk: high
Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases. For the f
Cocrystal Pharma Files 2024 10-K — Mar 31, 2025 Risk: medium
Cocrystal Pharma, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as BIOZONE PHARMACEUTICALS, INC., is based in Bo
Cocrystal Pharma, Inc. Files 2023 Annual Report on Form 10-K — Mar 28, 2024 Risk: low
Cocrystal Pharma, Inc. (COCP) filed a Annual Report (10-K) with the SEC on March 28, 2024. Cocrystal Pharma, Inc. filed its 2023 Form 10-K on March 28, 2024. Th

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX